logo

ENTX

Entera Bio·NASDAQ
--
--(--)
--
--(--)
2.42 / 10
Underperform

ENTX's fundamental score is 2.42/10, reflecting significant operational issues. Key concerns include a 57.6% year-over-year revenue decline, a high days sales outstanding of 405 days, and a PB-ROE discrepancy of 3.96, all of which place the stock in lower performance quartiles. Only the interest coverage ratio and Profit-MV show moderate strength, but they are insufficient to offset broader weaknesses.

Fundamental(2.42)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight12.21%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value-57.58
Score2/3
Weight2.60%
1M Return1.11%
Days sales outstanding
Value405.00
Score0/3
Weight-10.75%
1M Return-5.18%
Profit-MV
Value0.46
Score2/3
Weight24.25%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight24.28%
1M Return8.45%
PB-ROE
Value3.96
Score0/3
Weight7.24%
1M Return2.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-2.43%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-57.58
Score2/3
Weight1.00%
1M Return0.43%
Asset-MV
Value-0.50
Score1/3
Weight17.75%
1M Return6.68%
Cash-MV
Value-0.07
Score2/3
Weight23.85%
1M Return8.41%
Is ENTX undervalued or overvalued?
  • ENTX scores 2.42/10 on fundamentals and holds a Premium valuation at present. Backed by its -72.26% ROE, -8694.35% net margin, -4.50 P/E ratio, 3.13 P/B ratio, and 7.69% earnings growth, these metrics solidify its Underperform investment rating.